LINE-1 retrotransposition is a recurrent cause of MET exon 14 skipping in cancer

This study identifies nine cases where LINE-1 retrotransposition insertions cause MET exon 14 skipping in cancer, establishing this mechanism as a recurrent and clinically actionable driver of oncogenic signaling.

The Gist

The Big Picture: A Glitch in the Genetic Blueprint

Imagine your body's cells are like a massive, complex factory. Inside every factory worker (cell) is a Instruction Manual (your DNA) that tells the factory how to build machines and run operations.

One specific machine in this factory is called MET. It's a "growth switch" that tells the cell when to grow and divide. Usually, this switch has a safety mechanism: a little "off" button (a specific part of the instruction manual called Exon 14) that tells the MET machine to shut down when it's done.

In some cancers, this "off" button gets broken. The MET machine gets stuck in the "ON" position, causing the factory to run wild and build too many cells. This is called MET Exon 14 Skipping. Doctors know this happens, and they have special medicines (like capmatinib) that can turn the switch off again.

The Mystery: How is the button breaking?

For a long time, scientists thought the "off" button was broken by tiny typos in the manual—like a missing letter or a swapped word (mutations).

But in this study, researchers found something new and surprising. In 9 different patients, the "off" button wasn't just broken by a typo. It was invaded.

The Villain: The "Genetic Squatter" (LINE-1)

Think of your DNA as a long book. Hidden inside this book are thousands of ancient, broken instructions called LINE-1 (L1). For millions of years, these have been like "ghosts" or "scaffolding" in the book—mostly harmless junk.

However, in some cancers, these ghosts wake up. They become active "copy-paste" machines. They can take a piece of their own code and jam it into a new spot in the instruction manual.

The Analogy:
Imagine you are reading a recipe for a cake. Suddenly, a sticky note with a random paragraph from a different book gets glued right into the middle of the instructions.

• The Result: The baker (the cell) gets confused. It sees the sticky note, skips the rest of the original instruction, and jumps straight to the next step. The cake comes out wrong.

In these 9 patients, the "sticky note" (the LINE-1 virus) glued itself right into the MET instruction manual, specifically right where the "off" button (Exon 14) should be. Because the manual was so cluttered with this foreign junk, the cell's machinery skipped over the "off" button entirely. The MET machine stayed stuck in "ON."

What the Researchers Found

The team looked at the DNA of nearly half a million patients. They found 9 cases where this "Genetic Squatter" (LINE-1) was the culprit.

1. It's Recurrent: This isn't just a one-time fluke. It happened in 9 different people with different types of cancer (lung, esophageal, stomach).
2. It's Sneaky: Standard DNA tests often miss this. They look for typos (missing letters), but they don't always look for "sticky notes" (large insertions). The researchers had to use a special "magnifying glass" (RNA sequencing) to see that the instructions were actually being skipped.
3. One Weird Case: In one patient, the squatter didn't just bring its own junk; it brought a piece of a different gene (RPS6) along for the ride. It was like the sticky note had a whole extra page glued to it!

Why This Matters (The "So What?")

This discovery is a big deal for three reasons:

• New Clues for Doctors: If a patient has cancer that looks like "MET Exon 14 Skipping" but standard tests can't find the cause, doctors now know to look for these "Genetic Squatters."
• Actionable Treatment: Even though the cause is weird (a viral insertion), the result is the same: the MET switch is stuck on. This means these patients can still be treated with the same MET inhibitor drugs that work for other patients. The treatment works on the result, not just the cause.
• Better Testing: It tells scientists that we need to build better tests. We can't just look for typos; we need to look for "sticky notes" and "glued-in pages" in our DNA to catch all the ways cancer can hide.

Summary

Think of cancer as a factory running out of control. Usually, we know the switch is broken because someone erased a letter. This paper says, "Hey, sometimes the switch is broken because a genetic virus jumped in and glued a piece of trash right over the button."

Now that we know the trash is there, we can find the patients, fix the diagnosis, and give them the medicine they need to turn the factory back to normal.

Technical Summary

1. Problem Statement

• Clinical Context: MET exon 14 skipping is a well-established oncogenic driver in non-small cell lung cancer (NSCLC) and other malignancies. It leads to the loss of the CBL E3 ubiquitin ligase binding site, preventing receptor degradation and causing sustained oncogenic signaling. This alteration confers sensitivity to MET tyrosine kinase inhibitors (TKIs) like capmatinib and tepotinib.
• Diagnostic Challenge: Detecting the genetic cause of MET exon 14 skipping is technically difficult due to mutation heterogeneity. While most cases are caused by small base substitutions or indels near splice sites, others involve large deletions or complex structural variants.
• The Gap: Standard DNA-based Next-Generation Sequencing (NGS) assays often miss large insertions or complex rearrangements. Specifically, the role of LINE-1 (Long Interspersed Element-1) retrotransposition as a cause of MET exon 14 skipping had not been systematically characterized or reported as a recurrent, clinically actionable mechanism in cancer prior to this study.

2. Methodology

The study utilized a retrospective analysis of clinical genomic data from Foundation Medicine Inc.

• Cohort: The authors analyzed data from 461,708 patients with solid tumor biopsies (collected 2013–2025).
  • All cases underwent comprehensive DNA-based NGS (hybrid-capture of coding exons and flanking introns for MET).
  • A subset of 11,376 cases had paired RNA-based NGS.
  • A specific cohort of 2,296 patients with known MET exon 14 skipping alterations was examined in detail.
• Detection Strategy:
  • RNA Analysis: Identified MET exon 14 skipping via the detection of in-frame fusions between exons 13 and 15.
  • DNA Analysis (The Novel Approach): For cases where RNA showed skipping but DNA showed no canonical mutations, the authors performed a specialized bioinformatic search:
    1. Extracted sequencing reads from MET exon 14 and adjacent introns.
    2. Isolated "soft-clipped" reads (indicating potential structural variants).
    3. Performed BLASTn alignment against the human LINE-1 (L1.3) repetitive element database.
    4. Manually inspected breakpoints, Target Site Duplications (TSDs), and insertion sequences using Integrative Genomics Viewer (IGV).
  • Pseudogene Detection: For one specific case, reads mapping to the MET region were BLASTed against the human genome (taxid: 9606) to identify non-LINE-1 insertions, revealing an RPS6 pseudogene insertion.

3. Key Contributions

• Discovery of a Recurrent Mechanism: This is the first report identifying LINE-1 retrotransposition as a recurrent, driver mechanism for MET exon 14 skipping.
• Clinical Actionability: The study establishes that these insertions are not merely passenger mutations but are "clinically actionable" driver events, as they result in the same oncogenic phenotype (MET hyperactivation) as canonical mutations.
• Methodological Advancement: The paper demonstrates the necessity of combining DNA graph-based assembly and RNA sequencing to detect complex insertional mutagenesis that standard variant calling pipelines miss.
• Diversity of Insertions: The authors characterized a spectrum of insertion events, including:
  • Standard 5'-truncated LINE-1 insertions.
  • Inverted LINE-1 insertions.
  • Insertions carrying transduced sequences (3' transduction).
  • A unique LINE-1-mediated pseudogene insertion (involving the RPS6 gene).

4. Results

• Case Identification: The authors identified 9 distinct cases across multiple cancer types (5 lung, 2 esophageal, 1 gastric, and 1 lung adenosquamous) where LINE-1 insertions caused MET exon 14 skipping.
• Insertion Characteristics:
  • Locations: All insertions occurred within a hotspot interval: either 31 bp or 91 bp into exon 14, or 4 bp upstream of the exon start (within intron 13, overlapping the splice acceptor site).
  • Structure: Most insertions were 5'-truncated (ranging from ~39 bp to ~630 bp) and flanked by Target Site Duplications (TSDs).
  • Orientation: Some insertions were in the sense orientation, while others were inverted.
  • Pseudogene Case (Case E2): One case involved a 630 bp insertion of an RPS6 pseudogene (mediated by LINE-1 machinery) rather than a LINE-1 sequence itself. This was confirmed by a >70-fold enrichment of RPS6 reads in the MET capture region compared to other LINE-1 positive cases.
• Co-occurring Alterations:
  • The MET alterations were mutually exclusive with other major drivers (KRAS, EGFR, ALK, etc.), confirming MET as the primary driver.
  • Some cases harbored EGFR amplifications or MDM2/CDK4 amplifications, which are known to co-occur with MET exon 14 skipping.
• Validation: RNA sequencing in all 9 cases confirmed the presence of the MET exon 13–15 fusion transcript, validating that the DNA insertions functionally disrupt splicing.

5. Significance

• Therapeutic Implications: Patients with these rare LINE-1 mediated alterations are likely to respond to MET TKIs. Recognizing this mechanism prevents false negatives in standard DNA testing and ensures patients receive targeted therapy.
• Diagnostic Recommendations: The study underscores the critical value of RNA-based testing or specialized DNA assays capable of detecting non-canonical insertions (like LINE-1) for MET exon 14 skipping. Relying solely on standard DNA variant calling may miss these drivers.
• Biological Insight: It expands the understanding of somatic mosaicism in cancer, showing that retrotransposition is not just a source of genome instability but a specific, recurrent pathway for oncogene activation.
• Future Directions: The authors call for the development of genomic DNA assays specifically tailored to capture these events and suggest that future studies should correlate these specific molecular subtypes with clinical treatment responses.

In summary, this paper redefines the mutational landscape of MET exon 14 skipping, adding LINE-1 retrotransposition and pseudogene insertions to the list of known driver mechanisms, with direct implications for precision oncology diagnostics and treatment.